0R15 9025.0 0.0% 0R1E 9410.0 0.0% 0M69 None None% 0R2V 247.99 9682.643% 0QYR 1567.5 0.0% 0QYP 439.3701 -2.9016% 0RUK None None% 0RYA 1597.0 1.2682% 0RIH 195.55 0.0% 0RIH 191.4 -2.1222% 0R1O 225.5 9683.0803% 0R1O None None% 0QFP 10475.8496 107.8542% 0M2Z 252.573 0.2373% 0VSO 33.0 -7.3164% 0R1I None None% 0QZI 622.0 0.0% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 222.05 -4.1318%

Beximco Pharmaceuticals Limited

Healthcare GB BXP

37.7GBP
1.20(3.29%)

Last update at 2024-12-19T09:58:00Z

Day Range

35.0037.70
LowHigh

52 Week Range

30.5950.52
LowHigh

Fundamentals

  • Previous Close 36.50
  • Market Cap458.25M
  • Volume6099
  • P/E Ratio5.86
  • Dividend Yield6.26%
  • EBITDA9085.88M
  • Revenue TTM40638.83M
  • Revenue Per Share TTM91.07
  • Gross Profit TTM 15714.02M
  • Diluted EPS TTM0.07

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax 6068.77M 6686.95M 6377.55M 4653.44M 3946.07M
Minority interest 89.60M 124.51M -38.05602M 302.33M 276.01M
Net income 4614.07M 5123.14M 5127.69M 3514.69M 3033.40M
Selling general administrative 1180.12M 1163.41M 896.65M 792.95M 752.94M
Selling and marketing expenses 8917.01M 7749.56M 6376.15M 5496.65M 4801.23M
Gross profit 17313.37M 15814.25M 13923.50M 11899.10M 10620.34M
Reconciled depreciation - 370.24M 203.96M 193.82M 166.04M
Ebit 7216.24M 6901.29M 6650.71M 5609.49M 5066.17M
Ebitda 7354.47M 7688.78M 7236.23M 5667.24M 4975.83M
Depreciation and amortization 138.23M 787.49M 585.53M 57.75M -90.34529M
Non operating income net other - - - - -
Operating income 7216.24M 6901.29M 6650.71M 5609.49M 5066.17M
Other operating expenses 32364.85M 28127.11M 23165.62M 20238.26M 17951.39M
Interest expense 1285.70M 1001.84M 858.69M 1013.80M 1029.76M
Tax provision 1544.30M 1688.32M 1211.80M 1108.96M 905.66M
Interest income - 3.06M 2.38M 20.41M 8.74M
Net interest income -1285.69825M -1001.83552M -858.68515M -993.39479M -993.31949M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1544.30M 1688.32M 1211.80M 1108.96M 905.66M
Total revenue 39266.66M 34669.17M 29493.57M 25611.95M 22816.63M
Total operating expenses 10411.56M 9272.19M 7595.54M 6525.41M 5755.11M
Cost of revenue 21953.29M 18854.92M 15570.07M 13712.85M 12196.29M
Total other income expense net -1147.47102M -214.34095M -273.15915M -956.05416M -1120.10783M
Discontinued operations - - - - -
Net income from continuing ops 4524.47M 4998.63M 5165.75M 3544.48M 3040.40M
Net income applicable to common shares - 5123.14M 5127.69M 3514.69M 3033.40M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 69156.78M 66148.04M 52246.08M 50118.74M 49214.09M
Intangible assets 4721.03M 4562.99M 1380.69M 1275.56M 1334.92M
Earning assets - - - - -
Other current assets - 17250.58M 788.81M 5693.76M 5680.14M
Total liab 21537.12M 21512.03M 14881.22M 17321.29M 19349.77M
Total stockholder equity 43680.70M 40600.50M 37030.56M 32495.12M 29588.32M
Deferred long term liab - - - - -
Other current liab 1672.25M 1354.38M 591.61M 1042.49M 764.85M
Common stock 4461.12M 4461.12M 4461.12M 4055.56M 4055.56M
Capital stock 4461.12M 4461.12M 4461.12M 4055.56M 4055.56M
Retained earnings 30806.19M 27747.89M 24179.78M 20058.80M 17144.33M
Other liab - 5321.91M 4324.82M 4311.74M 4008.33M
Good will 674.57M 674.57M 546.69M 546.69M 546.69M
Other assets - 88.64M - 2.69M 6.32M
Cash 1135.69M 1168.67M 675.47M 635.02M 610.49M
Cash and equivalents - - - - -
Total current liabilities 13265.02M 12735.93M 9349.68M 11357.97M 12745.83M
Current deferred revenue - - 368.44M - -
Net debt 9476.21M 11202.03M 6955.84M 9869.25M 12874.29M
Short term debt 8061.07M 8916.51M 6424.59M 8852.67M 10889.17M
Short long term debt 6621.17M 6850.55M 5023.18M 8744.56M 10723.41M
Short long term debt total 10611.90M 12370.70M 7631.30M 10504.26M 13484.78M
Other stockholder equity 8413.39M 8391.49M 8389.65M 8380.76M 8388.42M
Property plant equipment - 42379.22M 36531.26M 35240.97M 34056.67M
Total current assets 20875.85M 18419.26M 13770.85M 13049.08M 13264.16M
Long term investments - - - - 5.33M
Net tangible assets - 35362.94M 35103.17M 30672.87M 27706.70M
Short term investments - - - - 323.36M
Net receivables 3574.65M -11124.09233M 4501.98M 3312.09M 3341.28M
Long term debt - 2997.43M 972.70M 1442.73M 2348.23M
Inventory 12953.02M 11124.09M 7804.59M 6720.30M 6650.16M
Accounts payable 3531.71M 2465.04M 1965.05M 1462.81M 1091.81M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - -10374.65187M -9397.35993M
Additional paid in capital - - - - -
Common stock total equity - - - 4055.56M 4055.56M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 20.97M 23.36M 16.59M 6.44M 6.32M
Deferred long term asset charges - - - - -
Non current assets total 48280.93M 47728.78M 38475.24M 37069.66M 35949.93M
Capital lease obligations - 617.34M 348.00M 316.98M 413.14M
Long term debt total - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -2617.01763M -7680.05442M -2524.64585M 323.36M 16.03M
Change to liabilities - -23.61365M 587.17M 371.00M 100.10M
Total cashflows from investing activities - -7680.05442M -2524.64585M -1946.86207M -4510.00050M
Net borrowings - 4238.32M -2879.81700M -2971.11457M 2271.98M
Total cash from financing activities -3560.57081M 2615.23M -3458.16802M -3573.07159M 1766.63M
Change to operating activities - 141.21M -146.06246M 72.98M -43.65519M
Net income 4614.07M 5123.14M 5127.69M 3514.69M 3033.40M
Change in cash -32.98764M 194.71M 40.45M 24.52M 216.76M
Begin period cash flow 1168.67M 973.96M 635.02M 610.49M 393.74M
End period cash flow 1135.69M 1168.67M 675.47M 635.02M 610.49M
Total cash from operating activities 6084.79M 5493.38M 6023.26M 5542.49M 2959.92M
Issuance of capital stock - - - 0.00000M 0.00010M
Depreciation - 370.24M 203.96M 193.82M 166.04M
Other cashflows from investing activities - 2.02M 0.94M 1.43M 1.49M
Dividends paid 1567.92M 1623.10M 578.35M 601.96M 505.35M
Change to inventory - -2565.07760M -1084.28836M -70.13890M -927.40016M
Change to account receivables - 352.25M 431.61M 29.51M -573.44951M
Sale purchase of stock - - - - -
Other cashflows from financing activities -1992.64743M 4238.32M -2879.81700M -2971.11457M 2271.98M
Change to netincome - 91.04M 895.57M 356.23M 697.39M
Capital expenditures 2710.03M 2939.50M 2558.42M 2275.30M 4545.07M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital - - - - -
Stock based compensation - - - - -
Other non cash items - -5493.37506M -5127.69371M -3708.50236M -3199.44365M
Free cash flow 3374.76M 2553.88M -2558.41772M 3267.19M -1585.14876M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (GBP) Price (GBP) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BXP
Beximco Pharmaceuticals Limited
1.20 3.29% 37.70 5.86 4.52 0.01 0.59 0.01 0.06
HLN
Haleon PLC
-3.3 0.86% 380.60 24.73 16.86 2.63 1.81 3.17 16.57
HIK
Hikma Pharmaceuticals PLC
7.00 0.36% 1935.00 33.45 11.14 1.45 2.32 1.76 8.98
HCM
HUTCHMED China Ltd
2.00 0.85% 238.00 - - 3.22 3.97 2.39 -19.4252
INDV
Indivior PLC
-32.0 3.38% 913.50 - - 1.60 48.69 1.17 -4.7616

Reports Covered

Stock Research & News

Profile

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It offers its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids. The company also exports its products. Beximco Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Dhaka, Bangladesh.

Beximco Pharmaceuticals Limited

19 Dhanmondi R/A, Dhaka, Bangladesh, 1205

Key Executives

Name Title Year Born
Mr. Nazmul Hassan MP MD & Director NA
Mr. Mohammad Ali Nawaz Chief Financial Officer NA
Mr. S. M. Rabbur Reza Chief Operating Officer NA
Mr. Jamal Ahmed Choudhury Director of Accounts & Fin. NA
Mr. Rizvi Ul Kabir Director of Marketing NA
Mr. M. A. Arshad Bhuiyan Gen. Mang. of HR NA
Mr. Zakaria Seraj Chowdhury Head of Distribution Services & Director of International Marketing NA
Mr. Mohammad Asad Ullah FCS Company Sec. NA
Mr. Prabir Ghose Exec. Director of Quality Assurance NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions